Strategy

Investment Objective

The fund seeks long-term capital appreciation.

Morningstar Equity Style

Large Growth

Data as of 07/31/2021

Average Annual Total Returns (Investor Class)

1 YR

33.28%

Benchmark

40.79%

Value

-7.51%

Data as of 06/30/2021

3 YR

20.01%

Benchmark

18.67%

Value

1.34%

Data as of 06/30/2021

5 YR

18.46%

Benchmark

17.65%

Value

0.81%

Data as of 06/30/2021

10 YR

19.55%

Benchmark

14.84%

Value

4.71%

Data as of 06/30/2021

Expense Ratio

Current Year Performance (Investor Class)

Daily YTD

16.37%

Benchmark

21.58%

Value

-5.21%

Data as of 08/31/2021

Monthly YTD

11.72%

Benchmark

17.99%

Value

-6.27%

Data as of 07/31/2021

One Month

2.02%

Benchmark

2.38%

Value

-0.36%

Data as of 07/31/2021

Three Months

6.76%

Benchmark

5.50%

Value

1.26%

Data as of 07/31/2021

Asset Allocation

Largest US Stock 84.86% $16.5b

Other View complete

Holdings

Largest Holding UnitedHealth Group 6.07% Was (03/31/2021) 6.17%

Other View complete Full Holdings

Top 10 Holdings 30.25% View the latest Top 10 Holdings

12-Month Portfolio Turnover 36.7% Data as of 07/31/2021

Largest Contributor

UnitedHealth Group

6.07%

Largest Detractor

Vertex Pharmaceuticals

2.22%

Purchase

Moderna therapeutics

1.69%

Was 0.96%

Sale

Abbott Laboratories (E)

0.00%

Was 0.72%

Sectors

Largest Sector Biotechnology 32.01% Was (06/30/2021) 32.36%

Other View complete

Contributor

Biotechnology

By 2.72%

Sector 0.51%

Selection 2.21%

Detractor

Life Sciences

By -0.12%

Sector 0.50%

Selection -0.62%

Fund 22.78%

Benchmark 13.08%

Under

Biotechnology

By -16.24%

Fund 32.01%

Benchmark 48.25%

Team (As of )

Ziad

Ziad Bakri, CFA, MD
Portfolio Manager

Ziad Bakri is a portfolio manager in the U.S. Equity Division of T. Rowe Price. He is president of the Investment Advisory Committee of the Health Sciences Strategy. In addition, he is a vice president and an Investment Advisory Committee member of the Blue Chip Growth, New America Growth, New Horizons, Mid-Cap Growth, and Tax-Efficient Equity Strategies. Mr. Bakri is also an Investment Advisory Committee member of the Global Growth Stock Strategy and a vice president of the Emerging Europe Strategy. Previously, he was an investment analyst in the U.S. Equity Division, covering biotechnology in the health care sector. Mr. Bakri is a vice president of T. Rowe Price Group, Inc.

  • Fund manager
    since 2016
  • Years at
    T. Rowe Price 10
  • Years investment
    experience 16

Brian

Brian Dausch, CFA
Portfolio Specialist

Brian Dausch is a portfolio specialist in the U.S. Equity Division. He is a member of the Global Natural Resources Equity, US Mid-Cap Growth Equity, US Small-Cap Growth Equity, QM US Small-Cap Growth Equity, and Health Sciences Equity Strategy teams, working closely with institutional clients, consultants, and prospects. He is a vice president of T. Rowe Price Group, Inc.

  • Years at
    T. Rowe Price 22
  • Years investment
    experience 23

How to Invest

View platform information
Share Class Min Initial Investment (USD) Min Subsequent Investment (USD) 12b-1 Fee Expense Ratio
Gross Net Limitation Type Limitation Expiration Date
Investor Class
Cusip 741480107
$2,500 $100 0.00% 0.76% 0.76% N/A N/A
I Class
Cusip 87281Y102
$1,000,000* N/A 0.00% 0.65% 0.65% N/A
N/A

Benefits & Risks

  • Rapid advances in the health care, medicine, and life sciences fields offer substantial opportunities for superior long-term capital appreciation.
  • The Fund is less diversified than other stock funds that invest in a wider range of industries and, therefore, could experience significant volatility.

Investor Profile

For investors with a long-term horizon who are willing to accept the risks involved in investing in a concentrated portfolio of investments.

Risk/Return Characteristics

Data as of 07/31/2021

Risk/Return (5 Years) Fund S&P 500 Index
Alpha 2.48% 0.00%
Beta 0.89 1.00
R-Squared 0.62 1.00
Annualized Std. Deviation 16.90% 14.83%
Information Ratio 0.05 0.00
Sharpe Ratio 0.98 1.08
Tracking Error 10.70% 0.00%

Asset Allocation (07/31/2021)

Category % of Total Net Assets Market Value (USD)
Convertibles 3.63% $703,834,267.39
Global ex-US Stock 11.10% $2,152,220,487.07
Preferred 0.61% $118,275,179.92
Reserves -0.20% ($38,778,747.51)
US Stock 84.86% $16,453,822,570.49
Total Allocation   $19,389,373,757.35

Platforms (Investor Class)

PlatformRetail InvestorInstitutional Investor
Pershing N/A NTF
TD Ameritrade NTF NTF
Schwab NTF NTF
Fidelity NTF NTF
E*Trade NTF N/A
  • NTF No Transaction Fee
  • TF Transaction Fee
  • N/A Not Available

Generic

Financial Professionals

Client liaisons are available Monday-Thursday from 8 a.m. to 6 p.m. ET and Friday from 8 a.m. to 5 p.m. ET.

Tel: 1-800-564-6958

Tell us about you

Find us at the office

Eastmond- Sukel street no. 62, 79540 Hanga Roa, Easter Island

Give us a ring

Jaquelinee Wrate
+74 201 709 645
Mon - Fri, 9:00-15:00

Reach out